BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38169606)

  • 1. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
    Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
    Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma.
    Liu S; Qin Z; Mao Y; Zhang W; Wang Y; Jia L; Peng X
    Oncoimmunology; 2022; 11(1):2130583. PubMed ID: 36211811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
    Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
    Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
    J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
    Moon JH; Lee SH; Koo BS; Kim JM; Huang S; Cho JH; Eun YG; Shin HA; Lim YC
    Oral Oncol; 2020 Dec; 111():104948. PubMed ID: 32771963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
    Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
    Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma.
    Tavares MO; Milan TM; Bighetti-Trevisan RL; Leopoldino AM; de Almeida LO
    J Oral Pathol Med; 2022 Jul; 51(6):529-537. PubMed ID: 35678235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BMI1
    Chen D; Wu M; Li Y; Chang I; Yuan Q; Ekimyan-Salvo M; Deng P; Yu B; Yu Y; Dong J; Szymanski JM; Ramadoss S; Li J; Wang CY
    Cell Stem Cell; 2017 May; 20(5):621-634.e6. PubMed ID: 28285905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma.
    Lee SH; Do SI; Lee HJ; Kang HJ; Koo BS; Lim YC
    Lab Invest; 2016 May; 96(5):508-16. PubMed ID: 26927514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RXRα-enriched cancer stem cell-like properties triggered by CDDP in head and neck squamous cell carcinoma (HNSCC).
    Jiang P; Xu C; Zhou M; Zhou H; Dong W; Wu X; Chen A; Feng Q
    Carcinogenesis; 2018 Feb; 39(2):252-262. PubMed ID: 29228308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
    Bae WJ; Koo BS; Lee SH; Kim JM; Rho YS; Lim JY; Moon JH; Cho JH; Lim YC
    Br J Cancer; 2017 Dec; 117(12):1810-1818. PubMed ID: 29096401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
    Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
    Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
    Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
    Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.
    Fukusumi T; Ishii H; Konno M; Yasui T; Nakahara S; Takenaka Y; Yamamoto Y; Nishikawa S; Kano Y; Ogawa H; Hasegawa S; Hamabe A; Haraguchi N; Doki Y; Mori M; Inohara H
    Br J Cancer; 2014 Jul; 111(3):506-14. PubMed ID: 24874475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse.
    Jia L; Zhang W; Wang CY
    Cell Stem Cell; 2020 Aug; 27(2):238-253.e6. PubMed ID: 32697949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.